Skip to main content
padlock icon - secure page this page is secure

Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer’s Disease

Buy Article:

$52.00 + tax (Refund Policy)

Memantine extended release (ER) significantly outperformed placebo on co-primary endpoints of Clinician’s Interview-based Impression of Change Plus Caregiver Input (CIBIC-Plus) and baseline to endpoint changes on the Severe Impairment Battery (SIB) in a 24-week, randomized trial (NCT00322153) in patients with moderate to severe Alzheimer’s disease taking a cholinesterase inhibitor (ChEI). A post hoc analysis compared patients receiving memantine ER/ChEI to placebo/ChEI for time to onset of response and if the response was maintained (achieving improvement at weeks 8, 12, or 18 and maintaining through endpoint/week 24) on the SIB, the Neuropsychiatric Inventory (NPI), CIBIC-Plus, and Activities of Daily Living (ADL) using Fisher exact test. A second post hoc analysis compared percentages of patients for all possible combinations of 2 to 4 assessments with either no decline or clinically notable response using Wald χ2. Significantly greater percentages of memantine ER/ChEI patients achieved an early response that was maintained on SIB, NPI, and CIBIC-Plus (P<0.05) versus placebo/ChEI. Significantly greater percentages of memantine ER/ChEI-treated patients achieved and maintained a clinically notable response on ADL/NPI, SIB/ADL/NPI, and SIB/ADL/CIBIC-Plus, compared with placebo/ChEI (P<0.05). Memantine ER results in early, maintained improvement in patients with moderate to severe Alzheimer’s disease concurrently taking ChEIs, compared with cholinesterase treatment alone.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: Activities of Daily Living; Neuropsychiatric Inventory; Severe Impairment Battery; donepezil; galantamine; rivastigmine

Document Type: Research Article

Affiliations: 1: Department of Psychiatry and Behavioral Neuroscience, Division of Geriatric Psychiatry, Saint Louis University, Saint Louis, MO 2: ATP Clinical Research, Costa Mesa, CA 3: Pentara Corporation, Salt Lake City, UT 4: Prescott Medical Communications Group, Chicago, IL 5: Allergan PLC, Madison, NJ

Publication date: July 1, 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more